KR20220123742A - Hdac 억제제와 pd-l1 억제제의 병용 요법 - Google Patents
Hdac 억제제와 pd-l1 억제제의 병용 요법 Download PDFInfo
- Publication number
- KR20220123742A KR20220123742A KR1020227029531A KR20227029531A KR20220123742A KR 20220123742 A KR20220123742 A KR 20220123742A KR 1020227029531 A KR1020227029531 A KR 1020227029531A KR 20227029531 A KR20227029531 A KR 20227029531A KR 20220123742 A KR20220123742 A KR 20220123742A
- Authority
- KR
- South Korea
- Prior art keywords
- sti
- administered
- compound
- cancer
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662335056P | 2016-05-11 | 2016-05-11 | |
| US62/335,056 | 2016-05-11 | ||
| PCT/US2017/032200 WO2017197140A1 (en) | 2016-05-11 | 2017-05-11 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
| KR1020187035902A KR102471590B1 (ko) | 2016-05-11 | 2017-05-11 | Hdac 억제제 및 pd-l1 억제제의 병용 요법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187035902A Division KR102471590B1 (ko) | 2016-05-11 | 2017-05-11 | Hdac 억제제 및 pd-l1 억제제의 병용 요법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220123742A true KR20220123742A (ko) | 2022-09-08 |
Family
ID=60267123
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187035902A Active KR102471590B1 (ko) | 2016-05-11 | 2017-05-11 | Hdac 억제제 및 pd-l1 억제제의 병용 요법 |
| KR1020227029531A Ceased KR20220123742A (ko) | 2016-05-11 | 2017-05-11 | Hdac 억제제와 pd-l1 억제제의 병용 요법 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187035902A Active KR102471590B1 (ko) | 2016-05-11 | 2017-05-11 | Hdac 억제제 및 pd-l1 억제제의 병용 요법 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10385131B2 (enExample) |
| EP (1) | EP3454843A4 (enExample) |
| JP (2) | JP7013388B2 (enExample) |
| KR (2) | KR102471590B1 (enExample) |
| CN (1) | CN109640985A (enExample) |
| AU (2) | AU2017264857B2 (enExample) |
| BR (1) | BR112018073328A2 (enExample) |
| CA (1) | CA3023546A1 (enExample) |
| EA (1) | EA201892581A1 (enExample) |
| IL (1) | IL262808B2 (enExample) |
| MA (1) | MA44990A (enExample) |
| MX (2) | MX390986B (enExample) |
| NZ (1) | NZ748058A (enExample) |
| TW (1) | TWI794171B (enExample) |
| WO (1) | WO2017197140A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2834548C (en) | 2011-04-28 | 2021-06-01 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| WO2014018979A1 (en) | 2012-07-27 | 2014-01-30 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| EP3262073A1 (en) | 2015-02-26 | 2018-01-03 | Merck Patent GmbH | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| CN114702586A (zh) | 2015-03-13 | 2022-07-05 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| KR102712880B1 (ko) | 2015-06-16 | 2024-10-02 | 메르크 파텐트 게엠베하 | Pd-l1 길항제 조합 치료 |
| US20190183870A1 (en) * | 2016-01-05 | 2019-06-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018013975A1 (en) | 2016-07-15 | 2018-01-18 | Viracta Therapeutics, Inc. | Hdac inhibitors for use with nk cell based therapies |
| IL265762B2 (en) * | 2016-10-06 | 2024-04-01 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| BR112019014235A2 (pt) | 2017-01-11 | 2020-03-17 | Rodin Therapeutics, Inc. | Inibidores bicíclicos de histona desacetilase |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| US11897867B2 (en) | 2017-08-04 | 2024-02-13 | Bayer Aktiengesellschaft | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| CA3071861A1 (en) | 2017-08-07 | 2019-02-14 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
| SG10201900072VA (en) | 2018-01-05 | 2019-08-27 | Gnt Biotech & Medicals Corp | A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy |
| EP3737405A4 (en) * | 2018-01-12 | 2021-10-06 | Viracta Therapeutics, Inc. | EPIGENETIC MODIFIERS FOR USE IN CELLULAR IMMUNOTHERAPY |
| CA3125731A1 (en) | 2018-01-12 | 2019-07-18 | KDAc Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
| IL309951A (en) * | 2018-07-13 | 2024-03-01 | Alkermes Inc | Histone deacetylase inhibitors |
| AU2019385370B2 (en) * | 2018-11-20 | 2025-04-03 | Shenzhen Chipscreen Biosciences, Co., Ltd. | Application of chidamide |
| AU2020215088A1 (en) | 2019-02-01 | 2021-07-22 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases |
| JP7565295B2 (ja) * | 2019-04-01 | 2024-10-10 | シャー，ホウン・サイモン | 栄養サプリメント |
| KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
| US11878009B2 (en) * | 2019-09-10 | 2024-01-23 | Great Novel Therapeutics Biotech & Medicals Corporation | Anticancer combination of chidamide and celecoxib salts |
| TW202114659A (zh) * | 2019-10-02 | 2021-04-16 | 德商４Ｓｃ製藥公司 | 用於癌症治療之含ｈｄａｃ抑制劑、ｃｔｌａ—４抑制劑及ｐｄ—１抑制劑或ｐｄ—ｌ１抑制劑之組合 |
| EP4054628A4 (en) * | 2019-11-05 | 2023-11-22 | Health Research, Inc. | COMBINATION THERAPY AGAINST CANCER |
| TW202128224A (zh) * | 2019-12-23 | 2021-08-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｐｄ－１抗體和組蛋白去乙醯化酶抑制劑的藥物組合及其用途、使用方法 |
| JP2023539246A (ja) * | 2020-08-25 | 2023-09-13 | フヤバイオ インターナショナル，エルエルシー | 腫瘍微小環境の遺伝的調節のための方法及び組成物 |
Family Cites Families (538)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH627446A5 (fr) | 1978-01-17 | 1982-01-15 | Debiopharm Sa | Nouveaux derives de la benzamide. |
| GB8302483D0 (en) | 1983-01-29 | 1983-03-02 | Beecham Group Plc | Compounds |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| CZ284687B6 (cs) | 1986-04-30 | 1999-02-17 | Dainippon Pharmaceutical Co., Ltd. | Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| JP2529912B2 (ja) | 1990-10-16 | 1996-09-04 | 帝国化学産業株式会社 | ベンズアミド誘導体 |
| US5395832A (en) | 1991-02-15 | 1995-03-07 | Hokuriku Seiyaku Co., Ltd. | Benzamide derivatives |
| TW219935B (enExample) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| US5236931A (en) | 1992-03-26 | 1993-08-17 | A. H. Robins Company, Incorporated | 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol |
| US5610052A (en) | 1992-08-26 | 1997-03-11 | Ribozyme Pharmaceuticals Inc. | Enzymatic RNA with activity to ras |
| WO1995029891A1 (en) | 1994-04-28 | 1995-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | N-(3-pyrrolidinyl)benzamide derivative |
| US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| JPH0823980A (ja) | 1994-07-15 | 1996-01-30 | Terumo Corp | 脳神経細胞のアポトーシス時に発現する核レセプターおよびそれをコードする核レセプター遺伝子 |
| KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5958792A (en) | 1995-06-07 | 1999-09-28 | Chiron Corporation | Combinatorial libraries of substrate-bound cyclic organic compounds |
| GB9525620D0 (en) | 1995-12-15 | 1996-02-14 | Glaxo Group Ltd | Chemical compounds |
| EP0827742A1 (en) | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
| GB9821483D0 (en) | 1998-10-03 | 1998-11-25 | Glaxo Group Ltd | Chemical compounds |
| JP3354090B2 (ja) | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| WO1998024893A2 (en) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM |
| GB9625145D0 (en) | 1996-12-03 | 1997-01-22 | Smithkline Beecham Plc | Novel compounds |
| JPH10330254A (ja) | 1997-04-01 | 1998-12-15 | Kissei Pharmaceut Co Ltd | 翼状片の進行および術後の再発抑制剤 |
| US6444849B1 (en) | 1997-06-25 | 2002-09-03 | Mitsubishi Chemical Corporation | Amide derivatives |
| WO1999005109A1 (en) | 1997-07-25 | 1999-02-04 | Tsumura & Co. | PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-β INHIBITORS CONTAINING THE SAME |
| PT1034298E (pt) | 1997-12-05 | 2012-02-03 | Scripps Research Inst | Humanização de anticorpo murino |
| US6140351A (en) | 1997-12-19 | 2000-10-31 | Berlex Laboratories, Inc. | Ortho-anthranilamide derivatives as anti-coagulants |
| US6673827B1 (en) | 1999-06-29 | 2004-01-06 | The Uab Research Foundation | Methods of treating fungal infections with inhibitors of NAD synthetase enzyme |
| JP4405602B2 (ja) | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ヒストン脱アセチル化酵素阻害剤 |
| HUP0102367A3 (en) | 1998-05-15 | 2002-11-28 | Astrazeneca Ab | Benzamide derivatives for the treatment of diseases mediated by cytokines |
| AU2055500A (en) | 1998-12-23 | 2000-07-31 | Eli Lilly And Company | Aromatic amides |
| JP2000256194A (ja) | 1999-01-06 | 2000-09-19 | Mitsui Chemicals Inc | 核内レセプタ作動薬およびその効果増強剤 |
| CA2362375A1 (en) | 1999-02-11 | 2000-08-17 | Younghong Song | Alkenyl and alkynyl compounds as inhibitors of factor xa |
| KR20010110668A (ko) | 1999-03-17 | 2001-12-13 | 다비드 에 질레스 | 아미드 유도체 |
| EP1162884A4 (en) | 1999-03-19 | 2002-07-24 | Vertex Pharma | LOW-DOSE ORAL COMPOSITIONS OF BUTYRATE COMPOSITIONS |
| JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
| US6511990B1 (en) | 1999-09-08 | 2003-01-28 | Sloan-Kettering Institute For Cancer Research | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| JP4360660B2 (ja) | 1999-11-09 | 2009-11-11 | 三井化学株式会社 | モノアシルフェニレンジアミン誘導体の精製法 |
| CA2382165A1 (en) | 1999-12-08 | 2001-06-14 | Genset S.A. | Full-length human cdnas encoding potentially secreted proteins |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| ATE489360T1 (de) | 2000-03-24 | 2010-12-15 | Methylgene Inc | Inhibitoren der histon-deacetylase |
| US7005439B2 (en) | 2000-06-20 | 2006-02-28 | Astrazeneca Ab | Compounds |
| EP1170008A1 (en) | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| JP2004509941A (ja) | 2000-09-29 | 2004-04-02 | プロリフィクス リミテッド | Ｈｄａｃインヒビターとしてのアミド結合を含むカルバミン酸化合物 |
| US20020103192A1 (en) | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US6706686B2 (en) | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| AR037460A1 (es) | 2001-11-30 | 2004-11-10 | Smithkline Beecham Plc | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion |
| US7993626B2 (en) | 2007-01-11 | 2011-08-09 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
| KR20050040907A (ko) | 2002-07-17 | 2005-05-03 | 타이탄 파머슈티컬즈 인코퍼레이티드 | 항종양 활성 증강용 화학요법제의 조합 |
| US20050215601A1 (en) | 2002-09-25 | 2005-09-29 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient |
| US8163896B1 (en) | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US7790867B2 (en) | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
| US20050054647A1 (en) * | 2002-12-27 | 2005-03-10 | Detlev Schuppan | New pharmaceutical combination |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| TWI287010B (en) | 2003-06-12 | 2007-09-21 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
| US9005613B2 (en) | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
| CN1284772C (zh) | 2003-07-04 | 2006-11-15 | 深圳微芯生物科技有限责任公司 | 具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂 |
| WO2005046516A2 (en) | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Medical implants and anti-scarring agents |
| US20130189364A1 (en) | 2004-07-09 | 2013-07-25 | Robert Sabin | Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections |
| NZ599464A (en) | 2005-02-03 | 2014-03-28 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| WO2006094286A2 (en) | 2005-03-04 | 2006-09-08 | John O'neil | Adult pancreatic derived stromal cells |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| WO2006135479A2 (en) | 2005-05-10 | 2006-12-21 | Angiotech International Ag | Anti-scarring agents, therapeutic compositions, and use thereof |
| WO2006121521A2 (en) | 2005-05-10 | 2006-11-16 | Angiotech International Ag | Soft tissue implants, anti-scarring agents, and therapeutic compositions |
| WO2006121518A2 (en) | 2005-05-10 | 2006-11-16 | Angiotech International Ag | Electrical devices, anti-scarring agents, and therapeutic compositions |
| WO2006121522A2 (en) | 2005-05-10 | 2006-11-16 | Angiotech International Ag | Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions |
| EP1948195A2 (en) | 2005-11-17 | 2008-07-30 | Innate Pharma | Improved methods of using phosphoantigen for the treatment of cancer |
| US20090247734A1 (en) | 2005-12-14 | 2009-10-01 | Hendrickson Wayne A | Chemically Derivatized CD4 and Uses Thereof |
| US20090275633A1 (en) | 2006-04-13 | 2009-11-05 | Oncomethylome Sciences Sa | Novel Tumour Suppressor |
| US20070292351A1 (en) | 2006-05-26 | 2007-12-20 | Methylgene, Inc. | Assay for efficacy of histone deacetylase inhibitors |
| JP5513118B2 (ja) | 2006-10-19 | 2014-06-04 | シグナル ファーマシューティカルズ，エルエルシー | ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用 |
| US7838234B2 (en) | 2007-01-30 | 2010-11-23 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
| AU2008293885A1 (en) | 2007-07-13 | 2009-03-05 | The John Hopkins University | B7-DC variants |
| WO2009023193A1 (en) | 2007-08-15 | 2009-02-19 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| CN101861151B (zh) | 2007-09-14 | 2014-08-13 | 梅特希尔基因公司 | 使用组蛋白脱乙酰基酶hdac1、hdac2和/或hdac3的选择性抑制剂和微管稳定剂的癌症组合治疗 |
| GB0802009D0 (en) | 2008-02-04 | 2008-03-12 | Chroma Therapeutics Ltd | Biomarkers of aminopeptidase inhibition |
| JP2009209090A (ja) | 2008-03-04 | 2009-09-17 | Mitsui Chemicals Inc | 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法 |
| EP2283862B1 (en) | 2008-06-02 | 2018-08-08 | The University of Tokyo | Combination treatment of cancer comprising anti-mfg-e8 antibody |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| US20160041153A1 (en) | 2008-11-12 | 2016-02-11 | Kirk Brown | Biomarker compositions and markers |
| CN101757626B (zh) | 2008-12-26 | 2012-12-12 | 鼎泓国际投资（香港）有限公司 | 含有胰岛素样生长因子-i受体抑制剂和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 |
| CN101756957B (zh) | 2008-12-26 | 2012-11-14 | 鼎泓国际投资（香港）有限公司 | 含有青蒿素及青蒿素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 |
| CN101837129B (zh) | 2009-03-19 | 2012-12-12 | 鼎泓国际投资（香港）有限公司 | 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用 |
| CN101836989B (zh) | 2009-03-19 | 2013-02-13 | 鼎泓国际投资（香港）有限公司 | 含有粉防己碱及粉防己碱类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 |
| AU2010315400B2 (en) | 2009-10-27 | 2016-07-21 | Caris Mpi, Inc. | Molecular profiling for personalized medicine |
| KR20120099715A (ko) | 2009-11-06 | 2012-09-11 | 인피니티 파마슈티칼스, 인코포레이티드 | 헷지혹 경로 억제제의 경구용 포뮬레이션 |
| CA2779843A1 (en) | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| JP2013511549A (ja) | 2009-11-20 | 2013-04-04 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | ヘッジホッグ関連癌の治療のための方法及び組成物 |
| SI2536706T1 (sl) | 2010-02-11 | 2017-10-30 | Celgene Corporation | Derivati arilmetoksi izoindolina in sestavki,ki jih vsebujejo ter metode uporabe le-teh |
| NZ602634A (en) | 2010-03-26 | 2015-06-26 | Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
| BR112012025593A2 (pt) | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | biomarcadores em circulação para doença |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US8993622B2 (en) | 2010-06-11 | 2015-03-31 | Eirium Ab | Antiviral compounds |
| WO2012006584A2 (en) | 2010-07-08 | 2012-01-12 | Infinity Pharmaceuticals, Inc. | Therapeutic regimens for hedgehog-associated cancers |
| US20120010230A1 (en) | 2010-07-08 | 2012-01-12 | Macdougall John R | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
| US20140148350A1 (en) | 2010-08-18 | 2014-05-29 | David Spetzler | Circulating biomarkers for disease |
| CN102441167B (zh) | 2010-10-12 | 2014-05-07 | 鼎泓国际投资（香港）有限公司 | 含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 |
| US9808434B2 (en) | 2011-01-27 | 2017-11-07 | City Of Hope | Compound for treating cancer and diabetes |
| EP2678448A4 (en) | 2011-02-22 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | CIRCULATING BIOMARKERS |
| WO2012167086A2 (en) | 2011-06-03 | 2012-12-06 | President And Fellows Of Harvard College | Methods of diagnosing and treating amyotrophic lateral sclerosis |
| CN103782174A (zh) | 2011-06-07 | 2014-05-07 | 卡里斯生命科学卢森堡控股有限责任公司 | 用于癌症的循环生物标志物 |
| BR112013032232A2 (pt) | 2011-06-16 | 2016-09-20 | Caris Life Sciences Switzerland Holdings S A R L | método de caracterização de câncer através do uso de biomarcador de ácido nucleico |
| AU2012298794A1 (en) | 2011-08-23 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Biomarkers predictive of therapeutic responsiveness to HSP90 inhibitors and uses thereof |
| WO2013039956A2 (en) | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating mood disorders |
| ES2619707T3 (es) | 2011-09-30 | 2017-06-26 | Dana-Farber Cancer Institute, Inc. | Péptidos terapéuticos |
| PT2785683T (pt) | 2011-11-30 | 2020-04-16 | Ludwig Inst For Cancer Res Ltd | Moduladores de célula inkt e métodos para o seu uso |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| EP2756093A4 (en) | 2012-02-01 | 2015-07-01 | Compugen Ltd | C10RF32 ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER |
| WO2013124867A1 (en) | 2012-02-21 | 2013-08-29 | Amrita Vishwa Vidyapeetham University | Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules |
| US20150152474A1 (en) | 2012-03-09 | 2015-06-04 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
| HK1207967A1 (en) | 2012-06-06 | 2016-02-19 | 比奥诺尔免疫有限公司 | Vaccine |
| BR112014030466A2 (pt) | 2012-06-06 | 2017-09-12 | Bionor Immuno As | peptídeos derivados de proteínas virais para uso como imunógenos e reagentes de dosagem |
| SG10201704992SA (en) | 2012-06-21 | 2017-07-28 | Compugen Ltd | Lsr antibodies, and uses thereof for treatment of cancer |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| CA2882292C (en) | 2012-08-13 | 2023-10-17 | The Rockefeller University | Treatment and diagnosis of melanoma |
| CN104379169A (zh) | 2012-08-14 | 2015-02-25 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| DK2897620T3 (da) | 2012-09-21 | 2020-08-17 | Intensity Therapeutics Inc | Fremgangsmåde til behandling af cancer |
| US20150272980A1 (en) | 2012-11-05 | 2015-10-01 | Pronai Therapeutics, Inc. | Dosing and Administration of Oligonucleotide Cancer Therapies |
| CA2890288A1 (en) | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | Novel heterocyclic derivatives as modulators of kinase activity |
| AU2013347838A1 (en) | 2012-11-26 | 2015-06-11 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
| CN103833626B (zh) | 2012-11-27 | 2015-11-25 | 深圳微芯生物科技有限责任公司 | 西达本胺的晶型及其制备方法与应用 |
| AU2013352261B2 (en) | 2012-11-29 | 2018-05-10 | Merck Patent Gmbh | Azaquinazoline carboxamide derivatives |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| KR102536723B1 (ko) | 2012-12-13 | 2023-05-30 | 이뮤노메딕스, 인코오포레이티드 | 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약 |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| EP2953645A4 (en) | 2013-02-07 | 2016-12-28 | Immunomedics Inc | PRO-MEDICINE FORM (P2PDOX) OF HIGHLY POWERFUL 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED CANCER THERAPY |
| WO2014122551A1 (en) | 2013-02-07 | 2014-08-14 | Koninklijke Philips N.V. | A lighting system having a controller that contributes to a selected light scene, and a method for controlling such a system |
| CN104056270B (zh) | 2013-02-21 | 2018-11-09 | 中国人民解放军军事医学科学院野战输血研究所 | 用于制备多器官损伤救治药物的组蛋白去乙酰化酶抑制剂 |
| EP2964649B1 (en) | 2013-03-05 | 2017-05-10 | Merck Patent GmbH | Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer |
| JP6409007B2 (ja) | 2013-03-05 | 2018-10-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 抗癌剤としての９−（アリールまたはヘテロアリール）−２−（ピラゾリル、ピロリジニルまたはシクロペンチル）アミノプリン誘導体 |
| EP2970130A4 (en) | 2013-03-14 | 2016-08-03 | Seragon Pharmaceuticals Inc | MODULATORS OF POLYCYCLIC STROGEN RECEPTORS AND USES THEREOF |
| PL2970473T3 (pl) | 2013-03-14 | 2018-01-31 | Bristol Myers Squibb Co | Kombinacja agonisty dr5 i antagonisty anty-pd-1 oraz metody stosowania |
| US20160040163A1 (en) | 2013-03-15 | 2016-02-11 | Pronai Therapeutics, Inc. | Dnai for the modulation of genes |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| AU2014228502A1 (en) | 2013-03-15 | 2015-08-20 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| AR095363A1 (es) * | 2013-03-15 | 2015-10-14 | Genentech Inc | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 |
| CN104069106A (zh) | 2013-03-27 | 2014-10-01 | 南通瑞思医药技术有限公司 | 苯甲酰胺类化合物在制备激活潜伏艾滋病病毒药物中的应用 |
| EA032326B1 (ru) | 2013-04-18 | 2019-05-31 | Иммьюн Дизайн Корп. | Монотерапия gla для применения в лечении рака |
| EP3003355A1 (en) | 2013-05-24 | 2016-04-13 | Cooper Human Systems LLC | Methods and compositions for treatment of hiv infection |
| WO2014193999A2 (en) | 2013-05-28 | 2014-12-04 | Caris Science, Inc. | Biomarker methods and compositions |
| WO2014205136A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| BR112015031903A8 (pt) | 2013-06-19 | 2019-12-31 | Seragon Pharmaceuticals Inc | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto |
| US9662311B2 (en) | 2013-06-21 | 2017-05-30 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| KR20160037986A (ko) | 2013-07-29 | 2016-04-06 | 메르크 파텐트 게엠베하 | 1,3-디치환된 시클로펜탄 유도체 |
| US9751832B2 (en) | 2013-07-30 | 2017-09-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
| CA2919948C (en) | 2013-07-31 | 2020-07-21 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| ES2632988T3 (es) | 2013-07-31 | 2017-09-18 | Merck Patent Gmbh | Derivados de oxoquinazolinil-butanamida |
| CA2920377A1 (en) | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| HUE037134T2 (hu) | 2013-08-07 | 2018-08-28 | Merck Patent Gmbh | Piperidin-karbamid-származékok |
| US20160201063A1 (en) | 2013-08-16 | 2016-07-14 | Rana Therapeutics, Inc. | Epigenetic regulators of frataxin |
| CN103432077A (zh) | 2013-08-21 | 2013-12-11 | 北京淦航医药科技有限公司 | 西达苯胺固体分散制剂 |
| WO2015035112A1 (en) | 2013-09-05 | 2015-03-12 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
| US20160272707A1 (en) | 2013-09-11 | 2016-09-22 | Compugen Ltd. | Vstm5 antibodies, and uses thereof for treatment of cancer, infectious diseases and immune related diseases |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| US20150094518A1 (en) | 2013-09-27 | 2015-04-02 | The Regents Of The University Of California | Modular polymer platform for the treatment of cancer |
| SG11201602387RA (en) | 2013-10-21 | 2016-05-30 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
| CA2965114A1 (en) | 2013-10-21 | 2015-04-30 | Hemoshear, Llc | In vitro model for a tumor microenvironment |
| US20170080093A1 (en) | 2013-10-22 | 2017-03-23 | Tyme, Inc. | Tyrosine Derivatives And Compositions Comprising Them |
| EP3060563B1 (en) | 2013-10-25 | 2018-05-02 | Novartis AG | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| WO2015069266A1 (en) | 2013-11-07 | 2015-05-14 | Flynn Daniel L | Methods for inhibiting tie2 kinase useful in the treatment of cancer |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| US10758636B2 (en) | 2013-11-12 | 2020-09-01 | Centre For Probe Development And Commercialization | Residualizing linkers and uses thereof |
| KR20160084438A (ko) | 2013-11-13 | 2016-07-13 | 노파르티스 아게 | 면역 반응을 강화하기 위한 mTOR 억제제 |
| CN106029076B (zh) | 2013-11-18 | 2019-06-07 | 福马疗法公司 | 作为bet溴域抑制剂的苯并哌嗪组合物 |
| RS61519B1 (sr) | 2013-11-18 | 2021-03-31 | Forma Therapeutics Inc | Sastavi tetrahidrohinolina kao inhibitori bet bromodomena |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| CA2932767A1 (en) | 2013-12-06 | 2015-06-11 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| WO2015086738A2 (en) | 2013-12-11 | 2015-06-18 | Bionor Immuno As | Hiv vaccine |
| WO2015089380A2 (en) | 2013-12-12 | 2015-06-18 | Celcuity Llc | Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent |
| US20160263092A1 (en) | 2013-12-19 | 2016-09-15 | Twi Biotechnology, Inc. | Therapeutic uses of berberine formulations |
| ES2883289T3 (es) | 2013-12-20 | 2021-12-07 | Astex Therapeutics Ltd | Compuestos heterocíclicos bicíclicos y sus usos en terapia |
| BR112016014410A2 (pt) | 2013-12-20 | 2018-02-20 | The Broad Institute Inc. | terapia de combinação com vacina de neoantígeno |
| PL3087076T3 (pl) | 2013-12-23 | 2018-01-31 | Merck Patent Gmbh | Pochodne imidazopirazynonowe |
| WO2015096982A1 (de) | 2013-12-23 | 2015-07-02 | Bayer Pharma Aktiengesellschaft | Binder-konjugate (adcs) mit ksp-inhibitoren |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| CN104771363A (zh) | 2014-01-14 | 2015-07-15 | 深圳微芯生物科技有限责任公司 | 一种西达本胺固体分散体及其制备方法与应用 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US10143737B2 (en) | 2014-01-27 | 2018-12-04 | Bionor Pharma Asa | Method for the vaccination against HIV |
| AU2015208032B2 (en) | 2014-01-27 | 2020-07-30 | Bionor Immuno As | Dosage regimen for HIV vaccine |
| WO2015110659A1 (en) | 2014-01-27 | 2015-07-30 | Bionor Immuno As | Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response |
| US9631013B2 (en) | 2014-01-28 | 2017-04-25 | Fibrogen, Inc. | Therapeutic method for pancreatic cancer |
| WO2015113927A1 (en) | 2014-01-29 | 2015-08-06 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| EP3099682A1 (en) | 2014-01-29 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| WO2015120382A1 (en) | 2014-02-07 | 2015-08-13 | The Johns Hopkins University | Predicting response to epigenetic drug therapy |
| US9676757B2 (en) | 2014-02-27 | 2017-06-13 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
| CA2977839C (en) | 2014-02-28 | 2022-07-26 | The Royal Institution For The Advancement Of Learning / Mcgill University | Tc-ptp inhibitors as apc activators for immunotherapy |
| JP2017508469A (ja) | 2014-03-11 | 2017-03-30 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 癌悪性度、予後及び治療に対する反応性の決定 |
| AU2015228859A1 (en) | 2014-03-13 | 2016-07-07 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| CA2941161A1 (en) | 2014-03-13 | 2015-09-17 | F.Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| KR20240110004A (ko) | 2014-03-14 | 2024-07-12 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| JP6701088B2 (ja) | 2014-03-19 | 2020-05-27 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物 |
| CN104974079A (zh) | 2014-04-02 | 2015-10-14 | C&C生物医药有限公司 | 苯胺相关化合物的酰胺衍生物及其组合物 |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| US12146874B2 (en) | 2014-04-03 | 2024-11-19 | University Of Maryland, Baltimore | Microtentacle imaging in patient tumor samples |
| CN106916100B (zh) | 2014-04-04 | 2020-09-15 | 深圳微芯生物科技股份有限公司 | 一种e构型苯甲酰胺类化合物及其药用制剂 |
| US9987258B2 (en) | 2014-04-06 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase as a modulator of PDL1 expression and activity |
| US10233170B2 (en) | 2014-04-08 | 2019-03-19 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use |
| NO2776305T3 (enExample) | 2014-04-23 | 2018-01-27 | ||
| JP2015209376A (ja) | 2014-04-24 | 2015-11-24 | 国立大学法人北海道大学 | 腫瘍特異的免疫増強剤 |
| ES2885451T3 (es) | 2014-04-30 | 2021-12-13 | Inspirna Inc | Inhibidores del transporte de creatina y usos de los mismos |
| WO2015168614A2 (en) | 2014-05-01 | 2015-11-05 | Board Of Regents Of The University Of Nebraska | Polymer compositions of histone deacetylase inhibitors and methods of use thereof |
| WO2015172747A1 (en) | 2014-05-16 | 2015-11-19 | Zhaoyin Wang | Spirocyclic molecules as mth1 inhibitors |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| WO2015184405A1 (en) | 2014-05-30 | 2015-12-03 | Medivation Technologies, Inc. | Aromatic compounds, compositions and uses thereof |
| WO2015191568A2 (en) | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature |
| TWI681954B (zh) | 2014-06-12 | 2020-01-11 | 美商西爾拉癌症醫學公司 | Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺 |
| KR20170012560A (ko) | 2014-06-13 | 2017-02-02 | 길리애드 사이언시즈, 인코포레이티드 | 포스파티딜이노시톨 3-키나제 억제제 |
| NZ726638A (en) | 2014-06-13 | 2018-04-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| AU2015274628B2 (en) | 2014-06-13 | 2018-03-15 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| HK1231477A1 (zh) | 2014-06-13 | 2017-12-22 | 吉利德科学公司 | 磷脂酰肌醇3-激酶抑制剂 |
| JP6383810B2 (ja) | 2014-06-13 | 2018-08-29 | ギリアード サイエンシーズ， インコーポレイテッド | ホスファチジルイノシトール３−キナーゼ阻害剤としてのキナゾリノン誘導体 |
| EP3154957B1 (en) | 2014-06-16 | 2019-11-20 | Fundacion para la Investigacion Medica Aplicada | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases |
| CN106715415B (zh) | 2014-06-17 | 2019-06-14 | 拜耳制药股份公司 | 3-氨基-1,5,6,7-四氢-4h-吲哚-4-酮 |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| MX2016017110A (es) | 2014-06-24 | 2017-05-01 | Gilead Sciences Inc | Inhibidores de fosfatidilinositol 3-cinasa. |
| CA2953807A1 (en) | 2014-06-26 | 2015-12-30 | Yale University | Compositions and methods to regulate renalase in the treatment of diseases and disorders |
| EP3166633A1 (en) * | 2014-07-11 | 2017-05-17 | Bionor Immuno AS | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
| AU2015287773B2 (en) | 2014-07-11 | 2018-03-29 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of HIV |
| US10869926B2 (en) | 2014-07-15 | 2020-12-22 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| CN104083763A (zh) | 2014-07-16 | 2014-10-08 | 中国人民解放军军事医学科学院野战输血研究所 | 组蛋白去乙酰化酶抑制剂在制备潜伏病毒激活剂中的应用 |
| JP2017522324A (ja) | 2014-07-17 | 2017-08-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用 |
| WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
| US20170217946A1 (en) | 2014-07-25 | 2017-08-03 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| US10335460B2 (en) | 2014-07-29 | 2019-07-02 | Novartis Ag | IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions |
| TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| EP3177292B1 (en) | 2014-08-07 | 2020-11-25 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| GB201414464D0 (en) | 2014-08-14 | 2014-10-01 | Technion Res & Dev Foundation | Compositions and methods for therapeutics prescreening |
| AU2015304438B2 (en) | 2014-08-18 | 2019-06-20 | Ono Pharmaceutical Co., Ltd. | Acid-addition salt of Trk-inhibiting compound |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| JP6691715B2 (ja) | 2014-08-19 | 2020-05-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 局所的薬物送達のためのインプラント及びその使用 |
| JP2017525721A (ja) | 2014-08-26 | 2017-09-07 | ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ | 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品 |
| ES2695700T3 (es) | 2014-08-29 | 2019-01-10 | Gilead Sciences Inc | Agentes antirretrovirales |
| WO2016036759A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
| EP3191127A1 (en) | 2014-09-13 | 2017-07-19 | Novartis AG | Combination therapies of egfr inhibitors |
| PT3194401T (pt) | 2014-09-16 | 2020-12-23 | Gilead Sciences Inc | Formas sólidas de modulador de recetor tipo toll |
| JP2017535514A (ja) | 2014-09-19 | 2017-11-30 | バイエル ファーマ アクチエンゲゼルシャフト | Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類 |
| WO2016041511A1 (en) | 2014-09-19 | 2016-03-24 | Yen-Ta Lu | Benzo-heterocyclic compounds and their applications |
| CN107148420A (zh) | 2014-09-19 | 2017-09-08 | 拜耳制药股份公司 | 苄基取代的吲唑类化合物 |
| EP3194379A1 (en) | 2014-09-19 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 inhibitors |
| CN107074825A (zh) | 2014-09-19 | 2017-08-18 | 拜耳制药股份公司 | 作为bub1激酶抑制剂的苄基取代的吲唑类化合物 |
| EP3198276B1 (en) | 2014-09-24 | 2023-09-20 | Exscientia GmbH | Monolayer of pbmcs or bone-marrow cells and uses thereof |
| CN104530413B (zh) | 2014-10-01 | 2017-08-25 | 厦门赛诺邦格生物科技股份有限公司 | 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质 |
| CN104530415B (zh) | 2014-10-01 | 2017-09-01 | 厦门赛诺邦格生物科技股份有限公司 | 一种异官能化y型聚乙二醇衍生物、制备方法及其生物相关物质 |
| CN104725628B (zh) | 2014-10-01 | 2018-04-17 | 厦门赛诺邦格生物科技股份有限公司 | 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质 |
| BR112017006664A2 (pt) | 2014-10-03 | 2017-12-26 | Novartis Ag | terapias de combinação |
| CA2960401C (en) | 2014-10-06 | 2022-07-26 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| KR102513870B1 (ko) | 2014-10-14 | 2023-03-23 | 노파르티스 아게 | Pd-l1에 대한 항체 분자 및 그의 용도 |
| WO2016061133A1 (en) | 2014-10-14 | 2016-04-21 | Riptide Bioscience, Inc. | Peptides having anti-inflammatory properties |
| WO2016061495A1 (en) | 2014-10-16 | 2016-04-21 | Predictive Therapeutics Ltd. | Atavarsitic systems and methods for biomarker discovery |
| WO2016065349A2 (en) | 2014-10-24 | 2016-04-28 | University Of Maryland, Baltimore | Short non-coding protein regulatory rnas (sprrnas) and methods of use |
| JP6829193B2 (ja) | 2014-10-27 | 2021-02-10 | ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ | がんを治療するための単独または併用療法におけるｃｃｒ５拮抗剤の使用 |
| NZ731789A (en) | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| ES2832711T3 (es) | 2014-10-31 | 2021-06-11 | Abbvie Biotherapeutics Inc | Anticuerpos anti-CS1 y conjugados anticuerpo fármaco |
| WO2016070051A2 (en) * | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| WO2016073759A1 (en) * | 2014-11-05 | 2016-05-12 | The Regents Of The University Of California | Combination immunotherapy |
| WO2016071477A1 (en) | 2014-11-07 | 2016-05-12 | Rheinische Friedrich-Wilhelms-Universität Bonn Institut Für Rekonstruktive Neurobiologie | Methods for assessing the treatment response of cancer patients and for treating cancer patients by analysing cpg methylation |
| TW201625692A (zh) | 2014-11-14 | 2016-07-16 | 諾華公司 | 抗體藥物結合物 |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| ES2978534T3 (es) | 2014-11-17 | 2024-09-13 | Cellectar Biosciences Inc | Análogos de éter de fosfolípidos como vehículos de fármacos contra el cáncer |
| SG10201807625PA (en) | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| US10526341B2 (en) | 2014-11-19 | 2020-01-07 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| WO2016081679A1 (en) | 2014-11-20 | 2016-05-26 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
| US20180148789A1 (en) | 2014-12-01 | 2018-05-31 | University Of Southern California | Methods for treating and assessing tumor invasion and metastasis |
| WO2016087488A1 (en) | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives |
| WO2016087490A1 (en) | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| AU2015357054A1 (en) | 2014-12-04 | 2017-06-29 | Abruzzo Theranostic S.R.L. | Humanized anti-Trop-2 monoclonal antibodies and uses thereof |
| CA2968352A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
| HRP20211002T1 (hr) | 2014-12-09 | 2021-09-17 | Bayer Aktiengesellschaft | 1,3-tiazol-2-il supstituirani benzamidi |
| WO2016094309A1 (en) | 2014-12-10 | 2016-06-16 | Myosotis | Inhibition of tnf signaling in cancer immunotherapy |
| EP3699589A1 (en) | 2014-12-12 | 2020-08-26 | Celcuity Inc. | Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients |
| US10485880B2 (en) | 2014-12-15 | 2019-11-26 | Bayer Pharma Aktiengesellschaft | Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies |
| WO2016100619A2 (en) | 2014-12-17 | 2016-06-23 | Rgenix, Inc. | Treatment and diagnosis of cancer |
| CN107406433A (zh) | 2014-12-18 | 2017-11-28 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的2,3‑二苯基色烯的衍生物 |
| MX2017008091A (es) | 2014-12-18 | 2017-10-31 | Bayer Pharma AG | Acidos piridil-cicloalquil-carboxilicos sustituidos, composiciones que los contienen y usos de los mismos. |
| PT3233852T (pt) | 2014-12-18 | 2020-09-10 | Hoffmann La Roche | Tetrahidro-pirido[3,4-b]indóis como moduladores do recetor de estrogénio e suas utilizações |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| JP6807841B2 (ja) | 2014-12-18 | 2021-01-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーター及びその使用 |
| US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
| LT3234184T (lt) | 2014-12-19 | 2019-07-10 | Epigenomics Ag | Cpg metilinimo aptikimo ir vėžio diagnostikos būdai |
| WO2016102493A1 (en) | 2014-12-22 | 2016-06-30 | Bayer Pharma Aktiengesellschaft | Imidazopyridine ezh2 inhibitors |
| US20180022750A1 (en) | 2014-12-23 | 2018-01-25 | Bayer Pharma Aktiengesellschaft | 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl-substituted imidazopyridazines |
| DE102014226903A1 (de) | 2014-12-23 | 2016-06-23 | Olympus Winter & Ibe Gmbh | HF-Hilfsstoff, medizinisches System und Verfahren zum selektiven Behandeln von Krebsgewebe |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| US10336702B2 (en) | 2014-12-23 | 2019-07-02 | Bergenbio Asa | Pharmaceutically active compounds |
| EP3237397B1 (en) | 2014-12-24 | 2018-11-21 | Gilead Sciences, Inc. | Isoquinoline compounds for the treatment of hiv |
| TW202237569A (zh) | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| AU2015371255B2 (en) | 2014-12-24 | 2018-09-27 | Gilead Sciences, Inc. | Fused pyrimidine compounds for the treatment of HIV |
| US20160200815A1 (en) * | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| WO2016112245A1 (en) | 2015-01-08 | 2016-07-14 | Hackensack University Medical Center | Ex vivo methods for minimizing risks and maximizing benefits of allogeneic blood and marrow transplantation |
| WO2016111834A1 (en) | 2015-01-09 | 2016-07-14 | Reiley Pharmaceuticals, Inc. | Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers |
| WO2016117666A1 (ja) | 2015-01-23 | 2016-07-28 | 国立大学法人鹿児島大学 | Ｈｉｖ－１感染細胞殺傷剤及びその用途 |
| EP3247353A4 (en) | 2015-01-23 | 2018-07-04 | Confluence Life Sciences, Inc. | Heterocyclic itk inhibitors for treating inflammation and cancer |
| EP3250567B1 (en) | 2015-01-28 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| KR102856422B1 (ko) | 2015-01-30 | 2025-09-04 | 온코슈틱스 인코포레이티드 | 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조 [1,2-a]피리도[3,4-e]피리미딘-5(1h)-온, 그것의 유사체, 및 그것의 염과 치료에서의 그것의 사용 방법 |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| MX383363B (es) | 2015-02-05 | 2025-03-13 | Merck Patent Gmbh | Compuestos macrociclicos como inhibidores de cinasas asociadas al receptor de interleucina1/4 (irak1/4) y usos de los mismos. |
| BR112017014970B1 (pt) | 2015-02-06 | 2022-11-16 | Merck Patent Gmbh | Macrociclos de piridazinona como inibidores de irak, seus usos, e composição farmacêutica |
| KR20170117113A (ko) | 2015-02-12 | 2017-10-20 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 면역 관문 저해제와 조합한 플리나불린의 용도 |
| WO2016133910A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| KR102595395B1 (ko) | 2015-02-20 | 2023-10-27 | 다이이찌 산쿄 가부시키가이샤 | 암의 병용 치료법 |
| PE20171789A1 (es) | 2015-03-02 | 2017-12-28 | Bristol Myers Squibb Co | Inhibidores del factor beta de crecimiento de transformacion (tgf-beta) |
| RS56787B1 (sr) | 2015-03-04 | 2018-04-30 | Gilead Sciences Inc | Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina |
| JP6867295B2 (ja) | 2015-03-09 | 2021-04-28 | バイエル ファーマ アクチエンゲゼルシャフト | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ |
| EA201791975A1 (ru) | 2015-03-09 | 2018-03-30 | Байер Фарма Акциенгезельшафт | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ |
| US20180271891A1 (en) | 2015-03-11 | 2018-09-27 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
| WO2016146542A1 (en) | 2015-03-13 | 2016-09-22 | Fondazione Telethon | Il-10-producing cd4+ t cells and uses thereof |
| WO2016149366A1 (en) | 2015-03-16 | 2016-09-22 | The Johns Hopkins University | Methods and compositions for treating cancer |
| US10946050B2 (en) | 2015-03-16 | 2021-03-16 | Imagilin Technology Llc | Compositions comprising probiotics and methods of use thereof |
| US10195237B2 (en) | 2015-03-16 | 2019-02-05 | Imagilin Technology Llc | Compositions and methods for treating inflammatory related diseases or conditions using Pediococcus acidilactici probiotics |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| WO2016153839A1 (en) | 2015-03-20 | 2016-09-29 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and vorinostat for treating cancer |
| CA2980297A1 (en) | 2015-03-20 | 2016-09-29 | Syndax Pharmaceuticals, Inc. | Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer |
| WO2016153948A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders |
| US10745667B2 (en) | 2015-03-23 | 2020-08-18 | Yao Tang | Methods of primary tissue culture and drug screening using autologous serum and fluids |
| EP3273944B1 (en) | 2015-03-25 | 2024-11-20 | The Regents of The University of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| US10302629B2 (en) | 2015-03-30 | 2019-05-28 | University Of Maryland, Baltimore | Compositions and methods for treating cancer by rational targeting of protein translation |
| TR201905009T4 (tr) | 2015-04-02 | 2019-05-21 | Gilead Sciences Inc | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. |
| SG11201707089WA (en) | 2015-04-13 | 2017-10-30 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| WO2016166600A1 (en) | 2015-04-15 | 2016-10-20 | Trojantec Technologies Ltd | Delivery of microrna using mesenchymal stem cell microparticles |
| WO2016168721A1 (en) | 2015-04-17 | 2016-10-20 | The Trustees Of The University Of Pennsylvania | Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy |
| IL255148B2 (en) | 2015-04-29 | 2023-04-01 | Radius Pharmaceuticals Inc | 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation |
| EP3288558B1 (en) | 2015-04-30 | 2022-05-11 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| CA2984991A1 (en) | 2015-05-04 | 2016-11-10 | Bionor Immuno As | Dosage regimen for hiv vaccine |
| MA42038A (fr) | 2015-05-05 | 2018-03-14 | Bayer Pharma AG | Dérivés de cyclohexane à substitution amido |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| US10314854B2 (en) | 2015-05-15 | 2019-06-11 | University Of Iowa Foundation | Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy |
| WO2016184973A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016184962A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| US20160339030A1 (en) | 2015-05-19 | 2016-11-24 | University Of Maryland, Baltimore | Treatment agents for inhibiting hiv and cancer in hiv infected patients |
| WO2016184963A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| BR112017024797A2 (pt) | 2015-05-20 | 2018-08-07 | The Broad Institute Inc. | neoantígenos partilhados |
| MA42133A (fr) | 2015-05-21 | 2021-06-02 | Chemocentryx Inc | Modulateurs du ccr2 |
| CN107708674A (zh) | 2015-05-22 | 2018-02-16 | 阿菲欧斯公司 | 联合hiv疗法 |
| US10053451B2 (en) | 2015-05-26 | 2018-08-21 | Genentech, Inc. | Heterocyclic estrogen receptor modulators and uses thereof |
| CN104892648A (zh) | 2015-05-27 | 2015-09-09 | 天津工业大学 | 一种负载抗肿瘤药物的靶向金属有机骨架的制备及用途 |
| WO2016189042A1 (en) | 2015-05-28 | 2016-12-01 | Bayer Pharma Aktiengesellschaft | Method for stratification of melanoma patients by determination of oxygen consumption, ppargc1a, ppargc1b and mitf levels |
| WO2016196471A1 (en) | 2015-06-02 | 2016-12-08 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
| CA2988306A1 (en) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| KR20190118688A (ko) | 2015-06-05 | 2019-10-18 | 미라젠 세러퓨틱스 인코포레이티드 | 피부 t 세포 림프종(ctcl) 치료용 mir-155 억제제 |
| EP3303302B1 (en) | 2015-06-08 | 2019-03-20 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| AU2015242210A1 (en) | 2015-06-15 | 2017-12-07 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic linkers for conjugation |
| US10766962B2 (en) | 2015-06-16 | 2020-09-08 | The Regents Of The University Of California | FZD7 specific antibodies and vaccines to treat cancer and control stem cell function |
| WO2016205566A1 (en) | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| US10975112B2 (en) | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
| WO2016202756A1 (en) | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds |
| WO2016202758A1 (en) | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds |
| CN108347929A (zh) | 2015-06-19 | 2018-07-31 | 波士顿大学托管委员会 | 用于治疗疱疹病毒诱导的病况的方法和组合物 |
| WO2015151079A2 (en) | 2015-06-20 | 2015-10-08 | Hangzhou Dac Biotech Co, Ltd | Auristatin analogues and their conjugates with cell-binding molecules |
| MX392478B (es) | 2015-06-22 | 2025-03-24 | Bayer Pharma AG | Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles. |
| US20180318438A1 (en) | 2015-06-23 | 2018-11-08 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies |
| WO2016207090A2 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Site specific homogeneous with ksp inhibitors |
| US10744205B2 (en) | 2015-06-23 | 2020-08-18 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies |
| WO2016210247A1 (en) | 2015-06-24 | 2016-12-29 | Duke University | New methods of use for an anti-diarrhea agent |
| CA2986930C (en) | 2015-06-24 | 2023-09-26 | Duke University | Chemical modulators of signaling pathways and therapeutic use |
| CA2990705A1 (en) | 2015-06-29 | 2017-01-05 | Abraxis Bioscience, Llc | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy |
| JP2018524350A (ja) | 2015-06-29 | 2018-08-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ＴＢＫ／ＩＫＫε阻害剤化合物及びその用途 |
| CN107921006A (zh) | 2015-06-29 | 2018-04-17 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法 |
| CA2990687A1 (en) | 2015-06-29 | 2017-01-05 | Syndax Pharmaceuticals, Inc. | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer |
| WO2017003908A1 (en) | 2015-06-30 | 2017-01-05 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
| TW201708210A (zh) | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Ｚｅｓｔｅ同源物２增強子之抑制劑 |
| EP3317246A4 (en) | 2015-07-04 | 2019-02-27 | Suzhou M-conj Biotech Co., Ltd. | SPECIFIC CONJUGATION OF A CELL BINDING MOLECULE |
| US10179123B2 (en) | 2015-07-07 | 2019-01-15 | Bayer Pharma Aktiengesellschaft | 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors |
| WO2017008046A1 (en) | 2015-07-08 | 2017-01-12 | Children's Hospital Medical Center | Loss of transcriptional fidelity leads to immunotherapy resistance in cancers |
| JP6853234B2 (ja) | 2015-07-09 | 2021-03-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｂｔｋ阻害剤としてのピリミジン誘導体及びその使用 |
| WO2017005711A1 (de) | 2015-07-09 | 2017-01-12 | Bayer Pharma Aktiengesellschaft | Phosphor- und schwefel-substituierte benzodiazepin-derivate |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| US10292961B2 (en) | 2015-07-15 | 2019-05-21 | Hangzhou Dac Biotech Co., Ltd. | Disulfur bridge linkers for conjugation of a cell-binding molecule |
| US10414734B2 (en) | 2015-07-16 | 2019-09-17 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors |
| GB201512869D0 (en) | 2015-07-21 | 2015-09-02 | Almac Diagnostics Ltd | Gene signature for minute therapies |
| EP3121166A1 (en) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| WO2017019767A1 (en) | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| KR20180072665A (ko) | 2015-07-28 | 2018-06-29 | 베타 캐트 파마슈티칼스, 인코포레이티드 | 안트라센-9,10-디온 디옥심 화합물 전구약물 및 이의 용도 |
| EP3124609A1 (en) | 2015-07-29 | 2017-02-01 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutics oligonucleotides |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| ES2939084T3 (es) | 2015-07-29 | 2023-04-18 | Onk Therapeutics Ltd | Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada |
| PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
| WO2017018476A1 (ja) | 2015-07-29 | 2017-02-02 | 塩野義製薬株式会社 | キナゾリン誘導体の塩またはその結晶およびそれらの製造方法 |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| NZ738875A (en) | 2015-07-31 | 2023-06-30 | Vascular Biogenics Ltd | Motile sperm domain containing protein 2 and cancer |
| WO2017024009A1 (en) | 2015-08-03 | 2017-02-09 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof |
| CN107921286A (zh) | 2015-08-05 | 2018-04-17 | 拜耳制药股份公司 | 1h‑吡咯‑3‑胺类化合物 |
| WO2017023994A1 (en) | 2015-08-06 | 2017-02-09 | Yale University | Small molecule based antibody-recruiting compounds for cancer treatment |
| CA2993624A1 (en) | 2015-08-07 | 2017-02-16 | Thomas Helledays Stiftelse For Medicinsk Forskning | Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma |
| US10363226B2 (en) | 2015-08-12 | 2019-07-30 | North Carolina State University | Platelet membrane-coated drug delivery system |
| WO2017025493A1 (en) | 2015-08-12 | 2017-02-16 | Bayer Pharma Aktiengesellschaft | Quinoline ezh2 inhibitors |
| EP3133165A1 (en) | 2015-08-17 | 2017-02-22 | F. Hoffmann-La Roche AG | Methods for personalizing patient cancer therapy with anti angiogenic compounds |
| US10633399B2 (en) | 2015-08-17 | 2020-04-28 | Channel Therapeutics, Inc. | Functionalized aminobenzoboroxoles |
| GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| WO2017034234A1 (ko) | 2015-08-21 | 2017-03-02 | 서울대학교 산학협력단 | Hdac 억제제 내성을 갖는 암 치료용 복합제제 |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| WO2017035230A1 (en) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| WO2017035453A1 (en) | 2015-08-26 | 2017-03-02 | The Johns Hopkins University | Compositions and methods for treating solid tumors |
| US11096934B2 (en) | 2015-09-01 | 2021-08-24 | The Broad Institute, Inc. | Compounds and methods useful for treating or preventing hematological cancers |
| KR102631377B1 (ko) | 2015-09-02 | 2024-01-29 | 신닥스 파마슈티컬스, 인크. | 조합 요법을 위한 환자의 선별 |
| US10588985B2 (en) | 2015-09-02 | 2020-03-17 | Wayne State University | Compositions and methods relating to RAD6 inhibition |
| AU2016315878A1 (en) | 2015-09-03 | 2018-03-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| DE102015012049A1 (de) | 2015-09-15 | 2017-03-16 | Merck Patent Gmbh | Verbindungen als ASIC-Inhibitoren und deren Verwendungen |
| DE102015012050A1 (de) | 2015-09-15 | 2017-03-16 | Merck Patent Gmbh | Verbindungen als ASIC-Inhibitoren und deren Verwendungen |
| ES2980858T3 (es) | 2015-09-15 | 2024-10-03 | Stichting Radboud Univ Medisch Centrum | Método mejorado para la expansión ex vivo de HSPC CD34+ en células NK usando un antagonista del receptor de aril hidrocarburos |
| NZ739676A (en) | 2015-09-18 | 2022-02-25 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
| KR102650026B1 (ko) | 2015-09-18 | 2024-03-22 | 메르크 파텐트 게엠베하 | Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도 |
| US20210393674A1 (en) | 2015-09-20 | 2021-12-23 | Air Cross, Inc. | Ozonolysis for activation of compounds and degradation of ozone |
| MX2018003291A (es) | 2015-09-21 | 2019-02-07 | Ifom Fondazione St Firc Di Oncologia Molecolare | Nuevas estrategias terapeuticas contra el cáncer de sangre. |
| AU2016328619B2 (en) | 2015-09-21 | 2020-07-16 | Opna Bio SA | Heterocyclic compounds and uses thereof |
| WO2017053823A1 (en) | 2015-09-25 | 2017-03-30 | Pharmacyclics Llc | Treatment using hdac inhibitors and immunotherapy |
| US20180271849A1 (en) | 2015-09-29 | 2018-09-27 | Kangpu Biopharmaceuticals, Ltd. | Pharmaceutical composition and application thereof |
| US10059697B2 (en) | 2015-09-30 | 2018-08-28 | Gilead Sciences, Inc. | Compounds and combinations for the treatment of HIV |
| WO2017055313A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| TW201725044A (zh) | 2015-10-01 | 2017-07-16 | 基利科學股份有限公司 | 用於治療癌症之btk抑制劑及查核點抑制劑之組合 |
| WO2017055316A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| US10544156B2 (en) | 2015-10-02 | 2020-01-28 | Pierre Fabre Medicament | Hemi-synthetic trilobine analogs for use as a drug |
| AU2016329075A1 (en) | 2015-10-02 | 2018-04-26 | Gilead Sciences, Inc. | Combinations of the BTK inhibitor GS-4059 with inhibitors selected from a JAK, ASK1, BRD and/or MMP9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
| JP6602470B2 (ja) | 2015-10-09 | 2019-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｍｄｍ２−ｐ５３阻害薬としてのスピロ［３ｈ−インドール−３，２‘−ピロリジン］−２（１ｈ）−オン化合物及び誘導体 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| WO2017063966A1 (en) | 2015-10-13 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds |
| CN105288648B (zh) | 2015-10-14 | 2018-11-06 | 东南大学 | 一种亲水性药物的磷脂化合物、其药物组合物及应用 |
| TW201732037A (zh) | 2015-10-15 | 2017-09-16 | 安瑟吉納西斯公司 | 自然殺手細胞及ilc3細胞及其用途 |
| WO2017063959A1 (de) | 2015-10-15 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren |
| US20190055563A1 (en) | 2015-10-19 | 2019-02-21 | Dana-Farber Cancer Institute, Inc. | Polymerase q as a target in hr-deficient cancers |
| US20170115275A1 (en) | 2015-10-23 | 2017-04-27 | Arizona Board Of Regents On Behalf Of Arizona State University | Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development |
| JP2018538247A (ja) | 2015-10-23 | 2018-12-27 | 第一三共株式会社 | Ａｍｌを処置することに用いるための医薬組成物およびそれを必要とする対象においてａｍｌを処置する方法 |
| JP6855472B2 (ja) | 2015-10-23 | 2021-04-07 | 第一三共株式会社 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
| WO2017074788A1 (en) | 2015-10-27 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for targeting cancer-specific sequence variations |
| EP3368689B1 (en) | 2015-10-28 | 2020-06-17 | The Broad Institute, Inc. | Composition for modulating immune responses by use of immune cell gene signature |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| RS63125B1 (sr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Antitela koja se specifično vezuju za pd-1 i njihova upotreba |
| AU2016349632A1 (en) | 2015-11-07 | 2018-05-24 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| CN105457038A (zh) | 2015-11-09 | 2016-04-06 | 东南大学 | 一种速释型药物磷脂化合物及其药物组合物 |
| CN116510015A (zh) | 2015-11-10 | 2023-08-01 | 耶鲁大学 | 用于治疗自身免疫疾病和癌症的组合物及方法 |
| CA3003548A1 (en) | 2015-11-12 | 2017-05-18 | Hookipa Biotech Ag | Arenavirus particles as cancer vaccines |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| EP3377068B1 (en) | 2015-11-20 | 2025-03-26 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
| EP3440579A4 (en) | 2015-11-24 | 2020-03-25 | Klaritos, Inc. | INNOVATIVE MODEL OF DELIVERY, PROCESSING AND PAYMENT FOR SPECIALIZED MEDICINES |
| US20190202926A1 (en) | 2015-12-01 | 2019-07-04 | Genmab B.V. | Anti-death receptor antibodies and methods of use thereof |
| EP3384050A4 (en) | 2015-12-03 | 2019-07-31 | Alfred Health | MONITORING THE TREATMENT OR PROGRESSION OF MYELOMA |
| EP3383865B1 (en) | 2015-12-03 | 2020-01-29 | Bayer Pharma Aktiengesellschaft | Furane derivatives as inhibitors of atad2 |
| WO2017096246A1 (en) | 2015-12-03 | 2017-06-08 | Temple University-Of The Commonwealth System Of Higher Education | Modulation of nad+ and nad+ metabolic pathways for treatment of disease |
| AR106949A1 (es) | 2015-12-04 | 2018-03-07 | Boehringer Ingelheim Int | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales |
| CN106821965A (zh) | 2015-12-04 | 2017-06-13 | 中国科学院大连化学物理研究所 | 一种维甲酸多药共递送纳米粒溶液及其制备和应用 |
| AU2016367306B2 (en) | 2015-12-09 | 2021-04-22 | Medizinische Universität Wien | Monomaleimide-functionalized platinum compounds for cancer therapy |
| US10969392B2 (en) | 2015-12-10 | 2021-04-06 | Vanderbilt University | Methods and systems for predicting response to immunotherapies for treatment of cancer |
| US10239935B2 (en) | 2015-12-15 | 2019-03-26 | Gilead Sciences, Inc. | Human immunodeficiency virus neutralizing antibodies |
| US11045547B2 (en) | 2015-12-16 | 2021-06-29 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
| US20200216439A1 (en) | 2015-12-16 | 2020-07-09 | Bayer Pharma Aktiengesellschaft | Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones |
| US10316049B2 (en) | 2015-12-17 | 2019-06-11 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
| US20180371093A1 (en) | 2015-12-17 | 2018-12-27 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| MY210123A (en) | 2015-12-17 | 2025-08-28 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| CN109069623A (zh) | 2015-12-18 | 2018-12-21 | 诺华股份有限公司 | 靶向CD32b的抗体及其使用方法 |
| EP3390387B1 (en) | 2015-12-18 | 2021-11-17 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| US20200268720A1 (en) | 2015-12-22 | 2020-08-27 | Glaxosmithkline Llc | Methods of use of a class iia hdac inhibitor |
| CA3048193A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
| US20190290759A1 (en) | 2015-12-28 | 2019-09-26 | Syndax Pharmaceuticals, Inc. | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer |
| US10189797B2 (en) | 2015-12-30 | 2019-01-29 | Duke University | Chemical modulators of immune checkpoints and therapeutic use |
| CN109310709A (zh) | 2015-12-30 | 2019-02-05 | 细胞基因公司 | T淋巴细胞生产方法和由此产生的t淋巴细胞 |
| US20190183870A1 (en) | 2016-01-05 | 2019-06-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| EP3400290B1 (en) | 2016-01-08 | 2023-04-05 | Replimune Limited | Oncolytic virus strain |
| US11648220B2 (en) | 2016-01-11 | 2023-05-16 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| CN108699057B (zh) | 2016-01-14 | 2021-11-09 | 拜耳医药股份公司 | 5-取代的2-(吗啉-4-基)-1,7-萘啶 |
| JP7109365B2 (ja) | 2016-01-19 | 2022-07-29 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｂｔｋ阻害剤を含む製剤／組成物 |
| US11963520B2 (en) | 2016-01-19 | 2024-04-23 | Celgene Corporation | Transgenic mouse expressing human cereblon |
| US10973843B2 (en) | 2016-01-27 | 2021-04-13 | University Of Maryland, Baltimore | Method for monitoring cancer and for regulation of semaphorin 4D to improve cancer immunotherapy regimens |
| JP2019503386A (ja) | 2016-01-28 | 2019-02-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用 |
| SI3408407T1 (sl) | 2016-01-29 | 2021-04-30 | Epigenomics Ag | Postopki za odkrivanje CPG metilacije iz tumorja pridobljene DNA v vzorcih krvi |
| BR112018015783A2 (pt) | 2016-02-01 | 2018-12-26 | Bayer Pharma AG | biomarcadores de copanlisibe |
| GB201601773D0 (en) | 2016-02-01 | 2016-03-16 | Renishaw Plc | Method |
| BR112018015782A2 (pt) | 2016-02-01 | 2019-01-02 | Bayer Pharma AG | biomarcadores de copanlisibe |
| WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
| EP3411063B1 (en) | 2016-02-02 | 2020-11-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer |
| CA3013412C (en) | 2016-02-04 | 2023-10-10 | Suzhou M-Conj Biotech Co., Ltd. | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |
| UY37113A (es) | 2016-02-05 | 2017-08-31 | Dana Farber Cancer Inst Inc | Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento |
| CN108778267A (zh) | 2016-02-08 | 2018-11-09 | 万春药业公司 | 包含妥卡雷琐或其类似物的组合物 |
| CN115969970A (zh) | 2016-02-10 | 2023-04-18 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan的组合 |
| WO2017143035A2 (en) | 2016-02-17 | 2017-08-24 | The Penn State Research Foundation | Method and therapeutic use of pign and other genes or genes products that pign interacts with for prognosis and treatment of hematological neoplasias |
| US11311540B2 (en) | 2016-02-17 | 2022-04-26 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| CA3015241A1 (en) | 2016-02-22 | 2017-08-31 | Onxeo | Combination therapies comprising immuno-oncology agents and belinostat |
| WO2017145162A1 (en) | 2016-02-23 | 2017-08-31 | Chaya Brodie | Generation of cancer stem cells and use thereof |
| US20170247690A1 (en) | 2016-02-25 | 2017-08-31 | Agenovir Corporation | Oncoviral treatment with nuclease and chemotherapeutic |
| AU2017228371A1 (en) | 2016-03-04 | 2018-09-13 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US11357849B2 (en) | 2016-03-07 | 2022-06-14 | Musc Foundation For Research Development | Anti-nucleolin antibodies |
| US10844066B2 (en) | 2016-03-08 | 2020-11-24 | Bayer Pharma Aktiengesellschaft | 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides |
| US20190054057A1 (en) | 2016-03-08 | 2019-02-21 | The Board Of Regents For Oklahoma State University Office Of Intellectual Property Management | Immune boosting dietary compounds for disease control and prevention |
| MX2018011046A (es) | 2016-03-14 | 2019-05-06 | Kiromic Inc | Composiciones y metodos para tratar canceres. |
| WO2017157418A1 (en) | 2016-03-15 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Combination of mknk1-inhibitors |
| US20190077856A1 (en) | 2016-03-15 | 2019-03-14 | Memorial Sloan Kettering Cancer Center | Method of treating diseases using kinase modulators |
| US20170268001A1 (en) | 2016-03-16 | 2017-09-21 | The University Of Chicago | Rnas with tumor radio/chemo-sensitizing and immunomodulatory properties and methods of their preparation and application |
| EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| EP3429513A4 (en) | 2016-03-18 | 2020-03-18 | Procept Biorobotics Corporation | MINIMALLY INVASIVE METHODS AND SYSTEMS FOR HEMOSTASIS OF CLOSED HEMORRHAGIC TISSUE VOLUME |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| US20170273926A1 (en) | 2016-03-24 | 2017-09-28 | Orbus Therapeutics, Inc. | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN105949114A (zh) | 2016-06-27 | 2016-09-21 | 山东川成医药股份有限公司 | 一种西达本胺的合成方法 |
| US20190282541A1 (en) | 2016-07-20 | 2019-09-19 | Eisai R&D Management Co., Ltd. | Use of eribulin and histone deacetylase inhibitors in the treatment of cancer |
| CN106866571B (zh) | 2017-01-20 | 2018-06-29 | 中国药科大学 | 杂环脲类化合物及其药物组合物和应用 |
| CN110248662B (zh) | 2017-02-13 | 2022-08-16 | 康朴生物医药技术（上海）有限公司 | 一种治疗前列腺癌的组合、药物组合物及治疗方法 |
| CN106916101B (zh) | 2017-02-15 | 2020-05-01 | 聚缘（上海）生物科技有限公司 | Nampt/hdac双靶点抑制剂及其制备方法 |
| CN107011238B (zh) | 2017-03-14 | 2020-05-01 | 北京化工大学 | 一类组蛋白去乙酰化酶抑制剂及其制备方法和用途 |
| JP7187486B2 (ja) | 2017-05-25 | 2022-12-12 | レイドス， インコーポレイテッド | Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド |
| US20190046513A1 (en) | 2017-08-10 | 2019-02-14 | Huya Bioscience International, Llc | Combination therapies of hdac inhibitors and tubulin inhibitors |
-
2017
- 2017-05-10 TW TW106115474A patent/TWI794171B/zh active
- 2017-05-11 WO PCT/US2017/032200 patent/WO2017197140A1/en not_active Ceased
- 2017-05-11 NZ NZ748058A patent/NZ748058A/en unknown
- 2017-05-11 BR BR112018073328-8A patent/BR112018073328A2/pt not_active Application Discontinuation
- 2017-05-11 CN CN201780042391.5A patent/CN109640985A/zh active Pending
- 2017-05-11 MA MA044990A patent/MA44990A/fr unknown
- 2017-05-11 EP EP17796856.7A patent/EP3454843A4/en active Pending
- 2017-05-11 MX MX2018013593A patent/MX390986B/es unknown
- 2017-05-11 CA CA3023546A patent/CA3023546A1/en active Pending
- 2017-05-11 KR KR1020187035902A patent/KR102471590B1/ko active Active
- 2017-05-11 EA EA201892581A patent/EA201892581A1/ru unknown
- 2017-05-11 KR KR1020227029531A patent/KR20220123742A/ko not_active Ceased
- 2017-05-11 US US15/592,929 patent/US10385131B2/en active Active
- 2017-05-11 JP JP2018559885A patent/JP7013388B2/ja active Active
- 2017-05-11 AU AU2017264857A patent/AU2017264857B2/en active Active
-
2018
- 2018-11-06 IL IL262808A patent/IL262808B2/en unknown
- 2018-11-07 MX MX2022001447A patent/MX2022001447A/es unknown
-
2019
- 2019-08-14 US US16/541,020 patent/US11535670B2/en active Active
-
2021
- 2021-10-12 JP JP2021167100A patent/JP7190548B2/ja active Active
-
2022
- 2022-04-27 AU AU2022202748A patent/AU2022202748A1/en not_active Abandoned
- 2022-11-23 US US17/993,567 patent/US20230151099A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3454843A1 (en) | 2019-03-20 |
| BR112018073328A2 (pt) | 2019-02-26 |
| MX390986B (es) | 2025-03-21 |
| US11535670B2 (en) | 2022-12-27 |
| IL262808B2 (en) | 2023-07-01 |
| US10385131B2 (en) | 2019-08-20 |
| CN109640985A (zh) | 2019-04-16 |
| EA201892581A1 (ru) | 2019-06-28 |
| AU2022202748A1 (en) | 2022-05-19 |
| MX2022001447A (es) | 2022-02-22 |
| EP3454843A4 (en) | 2020-01-01 |
| US20230151099A1 (en) | 2023-05-18 |
| CA3023546A1 (en) | 2017-11-16 |
| NZ748058A (en) | 2025-06-27 |
| MX2018013593A (es) | 2019-11-07 |
| TWI794171B (zh) | 2023-03-01 |
| AU2017264857B2 (en) | 2022-05-12 |
| KR20190022520A (ko) | 2019-03-06 |
| JP2022017295A (ja) | 2022-01-25 |
| JP7190548B2 (ja) | 2022-12-15 |
| IL262808A (en) | 2018-12-31 |
| US20200181267A1 (en) | 2020-06-11 |
| KR102471590B1 (ko) | 2022-11-29 |
| JP2019518741A (ja) | 2019-07-04 |
| IL262808B1 (en) | 2023-03-01 |
| JP7013388B2 (ja) | 2022-01-31 |
| WO2017197140A1 (en) | 2017-11-16 |
| AU2017264857A1 (en) | 2018-11-29 |
| US20170327583A1 (en) | 2017-11-16 |
| TW201808286A (zh) | 2018-03-16 |
| MA44990A (fr) | 2021-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250026832A1 (en) | Combination therapies of hdac inhibitors and pd-1 inhibitors | |
| US20230151099A1 (en) | Combination therapies of hdac inhibitors and pd-l1 inhibitors | |
| US20200383961A1 (en) | Triplet therapies of hdac inhibitors, pd-l1 and/or pd-1 inhibitors, and ctla-4 inhibitors | |
| US20220110924A1 (en) | Methods and compositions for genetic modulation of tumor microenvironments | |
| KR20250134694A (ko) | 심장 내약성 hdac 억제제를 포함하는 방법 및 조성물 | |
| HK40008034B (en) | Treatment of colon cancer with a combination of the hdac inhibitor hbi-8000 and a pd-l1 inhibitor | |
| HK40008034A (en) | Treatment of colon cancer with a combination of the hdac inhibitor hbi-8000 and a pd-l1 inhibitor | |
| EA045229B1 (ru) | Комбинация ингибиторов hdac и pd-1 и её применение для лечения рака толстой кишки | |
| BR122024004327A2 (pt) | Combinação, composição farmacêutica, kit, composto, uso de um inibidor da histona desacetilase (inibidor de hdac) e uso de um composto | |
| BR122024004326A2 (pt) | Combinação, composição farmacêutica, kit, composto, uso de um inibidor da histona desacetilase (inibidor de hdac) e uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20220825 Application number text: 1020187035902 Filing date: 20181211 |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220916 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230502 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20231004 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230502 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |